Hypothesis-Generating Brief: Vitamin D

Artifact

Living evidence brief from agent-v3-full-paper-live

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Add a narrative reconciliation between the 'significant source statistic' counts and the null/unclear direction codes for each source where the abstract reports a positive effect, so readers can see whether the null reflects absence of evidence or coding convention.
2. Tighten the corpus topical fit: either remove sources that are not meaningfully about Vitamin D (obesity/DLBCL; VDR in breast cancer prognosis; bladder-cancer cell-line cisplatin synergy; ZIKV macrophage transcriptomics) or explicitly flag them as mechanistic/adjacent boundary literature separate from a clinical Vitamin D evidence map.
3. Reconcile the 22 disagreement figure with the three pairwise tensions actually surfaced in Tensions and Gaps; either report a substantive source-pair count or clearly label the 22 as claim-level metadata throughout.
4. Clarify why Middelkoop 2024 (n=450 RCT, weekly 10,000 IU vitamin D3 in schoolchildren) is in scope for an evidence map on Vitamin D in older adults / aging, or explicitly broaden the scope statement to reflect pediatric and adult-trial inclusion.

Major issues

• Several cited sources (e.g., Hontecillas-Prieto 2025 on obesity/DLBCL; Streb 2024 on VDR in breast cancer; Zhou 2025 on bladder cancer cell lines; Ramirez-Mejia 2026 on Zika/macrophages; FrancoGedda 2025 protocol paper) have little to no direct bearing on Vitamin D geroprotection or healthy aging outcomes and substantially stretch the corpus's topical coherence.
• The Cardiometabolic outcome class is supported only by an obesity/DLBCL lymphomas trial whose primary exposure is BMI, with vitamin D mentioned in the title but not represented in the available snippet — this single-source slice does not constitute a meaningful cardiometabolic evidence base for Vitamin D.
• Cartesian adoption of 'null' direction coding for sources whose abstracts clearly report positive signals (e.g., Aquila 2023 reports significant irisin increases; Tirgar 2024 reports significant cytokine effects; Tao 2024 reports significant 25(OH)D increases) is conservative but creates internal friction: the manuscript simultaneously reports 'significant source statistic in X/Y' and 'direction coded null/unclear' without reconciling these into reader-facing directional language.
• The 22 'cross-source disagreements' headline figure is a claim-level count that risks overstating the substantive heterogeneity visible from the 13 sources; the Tensions and Gaps section surfaces only three pairwise contrasts, which is a discrepancy that should be clarified or reconciled.

Minor issues

• Repeated outcome-class disclaimers and the duplicated 'Outcome-class note' / 'Source-context map' prose at the top of the Findings Map and in the Evidence Landscape sections add noise; consolidate into one framing paragraph or appendix.
• Several source tier assignments (B2 for indirect primary research) and directness categorizations are inconsistently applied: e.g., Fox 2023 (population-based cohort with significant primary finding) is coded as both indirect and 'mixed' direction — clarify whether 'mixed' captures the supplement-vs-biomarker distinction or pooled null effects across the cohort.
• The Next-Study Design Recommendation's cardiometabolic priority is weakly justified given that the supporting source is a DLBCL treatment-response study, not a cardiometabolic primary investigation.
• Ramirez-Mejia 2026 is listed as year 2026 in the bundle but the manuscript retention window discusses 2026-06-29 retrieval; confirm and align dating.

Reviewer note

Evidence-map review of 'Vitamin D — full paper'. Triage: revise. The manuscript shows the right posture for an evidence map (explicit scope, broad-coded outcome classes, transparent null coding, Tensions and Gaps section), but several substantive issues blunt its claim support and topical coherence. Scope and search summary: The search summary is explicit and auditable (10 queries across 12 sources, 137 → 13 admission funnel, criteria listed). The evidence-honesty note about 7/13 null-coded sources is appropriately conservative for an evidence map. Source-attribution: Each finding is attributed by cited_as to a specific bundle entry, and citations cross-check against DOIs. However, several included sources are poor topical matches for a Vitamin D-in-aging evidence map (obesity/DLBCL, breast cancer VDR, bladder-cancer cell lines, Zika/macrophage transcriptomics, a systematic-review protocol). The corpus topical fit is weak, which is a real concern even for a heterogeneous evidence map. Heterogeneity and tensions: The Tensions and Gaps section appropriately surfaces three pairwise contrasts and declines to pool them. The 22-disagreement headline contradicts the substantive count surfaced; this needs reconciliation. Overclaim: Mild. The manuscript does not collapse into a single causal claim; in fact, it leans strongly conservative. But the conservative null coding coexists with 'significant source statistic' counts in a way that could mislead a casual reader about whether the underlying abstracts report effects. Limits and gaps: Limitations section covers evidence-role imbalance and endpoint heterogeneity well. Gaps/next-study section is concrete and actionable — a strength. Decision: revise, with bounded fixes around corpus curation, direction-code reconciliation, and clarifying the disagreement count.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis